![]() |
市場調查報告書
商品編碼
1496771
制酸劑市場:依藥物類別、劑型、適應症、通路分類 - 全球預測 2024-2030Antacids Market by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Formulation (Liquid, Powder, Tablet), Indication, Distribution Channel - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年制酸劑市場規模為68.5億美元,預計2024年將達72.4億美元,2030年將達到101.8億美元,複合年成長率為5.81%。
制酸劑是一種用於中和胃酸並緩解胃酸過多相關症狀的藥物。這包括胃灼熱、消化不良和胃部不適等症狀,這些症狀可以透過增加胃部的 pH 平衡來緩解。制酸劑有多種形式出售,包括錠劑、液體和粉末,用於緩解與胃食道逆流 (GERD)、胃灼熱和消化性潰瘍相關的症狀。全球胃食道逆流症 (GERD)、胃灼熱和其他胃部疾病的盛行率不斷增加,這增加了對制酸劑的需求。現代飲食和生活方式導致酸性消化不良和相關疾病的增加,進一步推動了對制酸劑的需求。旨在提高產品功效和減少副作用的持續研究和開發對市場成長有正面影響。然而,有關制酸劑核准和銷售的嚴格規定可能會延遲產品上市並阻礙市場成長。替代療法和酸相關疾病治療的可用性對市場成長構成了重大挑戰。此外,對天然和有機成分的研究正在取得進展,可以有效緩解缺氧及相關症狀,為市場成長創造機會。提高抗酸產品功效和作用持續時間的藥物傳輸技術創新正在進行中,為市場創造了成長潛力。
主要市場統計 | |
---|---|
基準年[2023] | 68.5億美元 |
預測年份 [2024] | 72.4億美元 |
預測年份 [2030] | 101.8億美元 |
複合年成長率(%) | 5.81% |
區域洞察
美洲地區的制酸劑市場是由胃食道逆流(GERD)和壓力性胃炎以及其他胃腸道疾病的高盛行率所推動的。在美國和加拿大等主要國家,消費者的偏好正趨向速效、調味和咀嚼產品。 EMEA(歐洲、中東和非洲)地區呈現多樣化的格局,因為歐盟國家由於嚴格的監管而優先考慮基於醫學證明的處方箋的治療。歐洲、中東和非洲市場的特點是全球製藥品牌眾多,人們對具有其他健康益處(例如益生菌)的制酸劑越來越感興趣。在文明病和自我治療日益成長的推動下,中東和非洲的制酸劑市場正在擴大。此外,在亞太地區,中國和印度不斷壯大的中階以及不斷成長的醫療保健支出正在推動制酸劑的廣泛採用。由於日本人口老化以及對預防性醫療保健的日益重視,制酸劑的使用在亞太地區正在擴大。印度國內制酸劑市場的推動因素包括生活方式的改變、速食消費的增加以及人們對非處方藥 (OTC) 認知的提高。
FPNV定位矩陣
FPNV 定位矩陣對於評估制酸劑市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對制酸劑市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在制酸劑市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[186 Pages Report] The Antacids Market size was estimated at USD 6.85 billion in 2023 and expected to reach USD 7.24 billion in 2024, at a CAGR 5.81% to reach USD 10.18 billion by 2030.
Antacid is a type of medication that is used to neutralize stomach acidity and alleviate symptoms associated with excess gastric acid. These include conditions such as heartburn, indigestion, and stomach upset, providing relief by increasing the pH balance in the stomach. The antacid products are available in various forms, including tablets, liquids, and powders to relieve symptoms associated with gastroesophageal reflux disease (GERD), heartburn, and peptic ulcers. The rising prevalence of GERD, heartburn, and other gastric ailments globally is driving the need for antacid products. Modern dietary habits and lifestyles contribute to increased incidences of acidity and related disorders, further propelling the demand for antacids. Continuous research and development aimed at enhancing product efficacy and reducing side effects positively impact market growth. However, stringent regulations regarding the approval and marketing of antacid products can delay product launches, hampering market growth. The availability of alternative therapies and treatments for acid-related disorders poses a significant challenge for market growth. Moreover, ongoing research into natural and organic ingredients can effectively relieve acidity and related conditions, creating opportunities for market growth. Ongoing innovation in drug delivery technologies to improve the efficacy and duration of action of antacid products, generating growth potential in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 6.85 billion |
Estimated Year [2024] | USD 7.24 billion |
Forecast Year [2030] | USD 10.18 billion |
CAGR (%) | 5.81% |
Regional Insights
In the Americas region, the antacids market is driven by a high prevalence of gastroesophageal reflux disease (GERD) and stress-induced gastritis, amongst other digestive disorders. Consumer preferences lean toward fast-acting, flavored, and chewable forms in major countries such as the United States and Canada. The EMEA region presents a diverse landscape for antacids as the EU countries prioritize medically proven, prescription-based treatments due to stringent regulations. The EMEA market is characterized by a strong presence of global pharmaceutical brands and a growing interest in antacids that offer additional health benefits, such as probiotics. The antacids market in the Middle East and Africa is expanding, driven by lifestyle diseases and an increasing preference for self-medication. Moreover, in the APAC region, the burgeoning middle-class population and increased healthcare spending in China and India are expanding the adoption of antacids in the region. The rising aging population in Japan and a strong focus on preventive healthcare bolster the use of antacids in the APAC region. The domestic antacids market in India is propelled by lifestyle changes, increased fast food consumption, and rising awareness of over-the-counter (OTC) remedies.
Market Insights
The market dynamics represent an ever-changing landscape of the Antacids Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antacids Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antacids Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
TUMS partners with DraftKings to introduce an innovative platform, TUMS Prop Bites. This unique initiative creates awareness about making free food predictions by offering a chance to compare their selections with others nationwide. The brand's antacid tablets and chews are crafted to immediately relieve heartburn. These chewable solutions address symptoms such as heartburn, acid indigestion, sour stomach, and discomfort. [Published On: 2024-01-17]
Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
Dexcel Pharma Ltd. announced its strategic acquisition of eight reputable over-the-counter (OTC) brands to diversify and strengthen its consumer healthcare offerings. The enhanced portfolio features well-known products such as EarCalm Spray, Sominex for sleep assistance, Wind-Eze as an antacid, Bisodol for indigestion relief, Cymex for cold sore treatment, Liberize for erectile dysfunction, Yeast Vite supplements, and MacKenzies Smelling Salts for catarrh and colds. [Published On: 2024-01-11]
Camber Pharmaceuticals Launches Generic Wellbutrin SR
Camber Pharmaceuticals expanded its product line by introducing Famotidine Powder for oral suspension, USP, a treatment developed to address various gastrointestinal conditions. Suitable for adults, this formulation effectively treats active duodenal and gastric ulcers, relieving the symptoms of non-erosive gastroesophageal reflux disease (GERD). [Published On: 2023-11-27]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antacids Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aero Healthcare AU Pty Ltd, Alcon Industries, Alkem Laboratories Ltd., Allegiant Health, AstraZeneca plc, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals, Inc., Cipla Limited, Daiichi Sankyo Company Limited, Dexcel Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Imerys S.A., J. B. Chemicals & Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Magmit Pharmaceutical Co., Ltd., Mankind Pharma Ltd., Marksans Pharma, Nestle S.A., Novartis AG, Perrigo Company plc, Pfizer Inc., Raritan Pharmaceuticals, Inc., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Swiss Chem Healthcare by Swastik Lifesciences, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals, Wonderbelly, and Zoic Pharmaceuticals Pvt. Ltd..
Market Segmentation & Coverage